Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Simultaneous Treatment of Multiple Metabolic Pathways Better at Blocking Brain Tumor Growth

By LabMedica International staff writers
Posted on 27 Jan 2011
Chemotherapy directed at two or more of the embryonic metabolic pathways active in brain tumors was significantly more effective in blocking tumor growth than was inhibition of any single pathway.

Multiple early developmental pathways including Notch, Hedgehog, and Wnt function in malignant brain tumors such as medulloblastoma and glioblastoma (GBM). More...
This fact raises the possibility that tumors might compensate for therapy directed against one pathway by upregulating a different one.

Investigators at Johns Hopkins University (Baltimore, MD, USA) carried out experiments designed to determine whether brain tumors show resistance to therapies against Notch, and whether targeting multiple pathways simultaneously would kill brain tumor cells more effectively than monotherapy. To this end, they worked with clusters of GBM cells growing in culture (neurospheres) and with fresh sample of cancerous tissue obtained from patients.

They reported in the December 15, 2010, issue of the journal Clinical Cancer Research that GBM cells were at least partially resistant to long-term treatment with the gamma-secretase Notch suppressor MRK-003. Blocking the Notch pathway in neurospheres caused increased activity in both the Hedgehog and Wnt pathways. Targeting Notch and Hedgehog simultaneously induced apoptosis, decreased cell growth, and inhibited colony-forming ability more dramatically than monotherapy.

Dual treatment of fresh glioblastoma samples with Notch and Hedgehog inhibitors decreased by 50% to 80% the number of colonies formed in culture and decreased the average size of neurospheres.

"Our study indicates it may be necessary to simultaneously target multiple development signaling pathways to prevent cancers from becoming resistant to therapy,” said senior author Dr. Charles Eberhart, associate professor of pathology, ophthalmology, and oncology at Johns Hopkins University. "A single agent is not likely to work for prolonged periods.”

"Clinical trials evaluating inhibitors of Hedgehog or Notch in a number of cancer types are currently under way at Johns Hopkins University and several other sites across the country, said Dr. Eberhart.” Further studies will examine the relationship among the Notch, Hedgehog, and Wnt pathways in glioblastoma and look for other signaling processes that help tumors become resistant to therapy.”

Related Links:

Johns Hopkins University



Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Rapid Molecular Testing Device
FlashDetect Flash10
Pipette
Accumax Smart Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.